Table 2.
Baseline Predictors of Treatment Outcome (SVR12)
| Predictors | Treatment-Naive Patients |
Treatment-Experienced Patients |
All Patients |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SVR12 (n = 18) | No SVR12a (n = 7) | P Values | SVR12 (n = 20) | No SVR12 (n = 5) | P Values | SVR12 (n = 38) | No SVR12b (n = 12) | P Values | OR (95% CI) | |
| Host factors | ||||||||||
| Age, mean, y | 55.9 | 61.0 | .02 | 58.6 | 59.8 | .46 | 57.3 | 60.5 | .02 | 0.82 (.68–.99) |
| Female, No. (%) | 7 (39) | 0 (0) | .13 | 8 (40) | 2 (40) | >.99 | 15 (39) | 2 (17) | .18 | 3.26 (.63–17.01) |
| Black, No. (%) | 3 (17) | 1 (14) | >.99 | 8 (40) | 2 (40) | >.99 | 11 (29) | 3 (25) | >.99 | 1.22 (.28–5.38) |
| BMI, mean, kg/m2 | 30.3 | 28.8 | .41 | 31.4 | 30.7 | .80 | 30.9 | 29.6 | .58 | 1.03 (.93–1.15) |
| IL28B CC genotype, No. (%) | 3 (17) | 2 (29) | .60 | 8 (40) | 2 (40) | >.99 | 11 (29) | 4 (33) | >.99 | 0.82 (.20–3.27) |
| IFNL4 TT/TT genotype, No. (%) | 1 (5) | 0 (0) | >.99 | 1 (5) | 0 (0) | >.99 | 2 (5) | 0 (0) | >.99 | ∞ |
| Baseline LDL, mean, mg/dL | 83.4 | 72.6 | .37 | 69.9 | 40.0 | .05 | 76.3 | 60.7 | .12 | 1.02 (.99–1.05) |
| Baseline hemoglobin A1C, mean, mmol/mol, derived (%) | 5.9 | 5.8 | .81 | 5.9 | 6.0 | .84 | 5.9 | 5.9 | .98 | 1.01 (.48–2.12) |
| Liver fibrosis score 3, No. (%) | 10 (59) | 4 (57) | >.99 | 12 (60) | 1 (20) | .16 | 22 (59) | 5 (42) | .28 | 2.05 (.55–7.70) |
| Self-reported nonadherence (≥2 missed doses), No. (%) | 3 (17) | 2 (29) | .60 | 4 (20) | 0 (0) | .55 | 7 (18) | 2 (17) | >.99 | 1.13 (.20–6.34) |
| Viral factors | ||||||||||
| HCV genotype 1b, No. (%) | 9 (50) | 1 (14) | .34 | 2 (10) | 0 (0) | >.99 | 11 (29) | 1 (8) | .25 | 4.48 (.52–39.01) |
| Baseline HCV RNA <6 million IU/mL, No. (%)c | 14 (78) | 5 (71) | >.99 | 16 (80) | 4 (80) | >.99 | 30 (79) | 9 (75) | >.99 | 1.25 (.27–5.73) |
| Absence of NS3, NS5A, or NS5B RAV with >5-fold resistance, No. (%) | 14 (78) | 6 (86) | >.99 | 16 (80) | 3 (60) | .56 | 30 (79) | 9 (75) | >.99 | 1.25 (.27–5.73) |
Abbreviations: BMI, body mass index; CI, confidence interval; HCV, hepatitis C virus; LDL, low-density lipoprotein; OR, odds ratio; RAV, resistance-associated variant; SVR12, sustained virologic response at 12 weeks after treatment completion.
a The no-SVR12 group includes 1 patient lost to follow-up and 6 who experienced virologic relapse.
b The no-SVR12 group includes 1 patient lost to follow-up and 11 who experienced virologic relapse.
c By Roche assay.